GSK specialty medicines grew YoY in Q1 2025, and it is now the main profit engine, offsetting the weakness in their vaccine ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

Earlier diagnoses and advancements in treatment options are providing hope for patients with endometrial cancer like Yaca.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Jemperli works by attaching itself to a protein on specific immune system cells, called T cells. This helps the T cells work better to find cancer cells and kill them, which slows or stops the ...

European Commission approved GSK's Jemperli with chemotherapy for advanced or recurrent endometrial cancer, covering 75% of cases. RUBY trial showed Jemperli combo reduced death risk by 31% and ...

Jemperli was discovered by AnaptysBio, Inc. and licensed to TESARO, Inc., under a collaboration and exclusive license agreement signed in March 2014.

Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development programme. A robust clinical trial programme includes ...

GSK ’s GSK -1.42% cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant’s oncology ...

Key Takeaways Jemperli plus chemotherapy demonstrated superior overall survival compared to Keytruda in advanced NSCLC, with a median OS of 20.2 months versus 15.9 months. The PERLA trial showed ...

Jemperli in combination with chemotherapy is the first immuno-oncology treatment approved in the frontline setting for this patient population in Singapore. [1,2] Latest published local registry ...

About Jemperli (dostarlimab-gxly) Jemperli, a programmed death receptor-1 (PD-1)-blocking antibody, is the backbone of GSK’s ongoing immuno-oncology-based research and development program.